Dna Synthesis Market 2033: $14.3B Forecast at 17.3% CAGR

The Dna Synthesis Market Report defines a market valued at $4.0 billion in 2025, expanding at a 17.3% compound annual rate to roughly $14.3 billion by 2033. Demand is not limited to a single geography or workflow. Nucleic acid synthesis now supports vaccine design, CAR-T reagents, CRISPR diagnostics, mRNA production, protein engineering and precision medicine discovery. Procurement decisions inside biopharmaceutical R&D teams have shifted from transactional primer purchases to strategic supplier partnerships that require shorter turnaround, reliable sequence fidelity and scalable GMP documentation.

The market is being pulled by a structural decline in sequencing costs, by the clinical expansion of genetic tests, and by a growing pipeline of nucleic acid therapeutics. Service providers that combine oligo and gene synthesis with bioinformatics, cloning and quality-control analytics are gaining share. The report segments the industry by service type, application and end use. In addition, the Synthetic Biology Market creates one of the strongest pull-through signals for library-scale gene synthesis because enabling technologies such as DNA assembly, genome editing and directed evolution all require DNA molecules at ever larger scale.

North America remains the anchor region, but Asia-Pacific is closing the gap faster than any other geography as China and Singapore add automated oligo capacity. Within product families, the Oligonucleotide Synthesis segment holds the largest revenue position because nearly every NGS, PCR, CRISPR and antisense oligonucleotide experiment starts with a synthesized primer or probe. Biopharmaceutical and diagnostics companies control the largest share of downstream spending, while academic and research institutes generate the largest order volume. The market outlook is positive, but pricing pressure, biosecurity compliance and specialized talent constraints will filter out undifferentiated capacity over the forecast period.

Oligonucleotide synthesis is the largest service type in this industry, contributing roughly 61% of global service revenue in 2025. The remaining share is distributed across gene synthesis, with gene fragments and full-length synthetic genes becoming a faster-growing complement. Oligonucleotide synthesis is dominant because it feeds a broader list of downstream workflows: PCR, quantitative PCR, NGS library prep, CRISPR guide RNA synthesis, in situ hybridization and therapeutic antisense drug screening.

Within the Oligonucleotide Synthesis Market, standard oligos shorter than 50 nucleotides continue to generate the highest unit volumes. These products are used as PCR primers, Sanger sequencing primers and indexing oligos, and they account for the bulk of high-throughput order line items. Custom oligos between 51 and 100 nucleotides are becoming more valuable because they carry chemical modifications such as fluorophores, locked nucleic acids, phosphorothioate backbones and affinity tags. Custom oligonucleotide synthesis is projected to grow above 18% annually, supported by diagnostic assay developers that need highly validated probes with consistent QC metrics.

The length split matters commercially. Standard synthesis often runs on high-throughput 96-well or 384-well platforms with low price per base. Custom synthesis moves to lower-volume, higher-price production with additional purification and mass spectrometry checks. For vendors, the revenue mix is therefore determined less by reaction capacity and more by the ability to automate modified oligo production and reduce rejection risk.

The Gene Synthesis Market is expanding at a slightly faster rate than the core oligo market as researchers outsource larger pieces of DNA instead of cloning them in-house. Constructs of 1,000 to 2,500 nucleotides are now routinely synthesized and sequence-verified before delivery to drug discovery labs. Buyers in the Custom Gene Synthesis Market are moving toward codon-optimized, methylation-free and CpG-reduced designs, especially for vaccine antigens and protein therapeutic development. Gene synthesis revenue is not displacing oligo synthesis; instead, it creates a service continuum from short primers to full-length gene libraries.

Oligo orders are commonly classified into four length bands: less than 50 nt, 51-100 nt, 101-150 nt and more than 150 nt. Standard primers below 50 nt are the lowest-cost product and face recurring margin erosion. Modified products in the 51-100 nt band support PCR probe design and NGS adapters, while oligos above 150 nt are used for DNA assembly and complex hybridization assays. Quality control is now the main competitive differentiator, as clients request PAGE or HPLC purification even for routine primers. This quality bar raises operational cost but also creates a barrier to new entry.

The Antisense Oligonucleotide Market is adding another dimension to the length and purity debate. Therapeutic antisense oligos require GMP-compliant synthesis, large-scale purification and full analytical characterization. The emergence of approved antisense drugs for rare neuromuscular diseases means vendors can no longer treat oligonucleotide synthesis as a simple laboratory reagent business. It is becoming a regulated pharmaceutical supply chain in which scale-up risk, impurity profile and patient safety matter as much as price per base.

The Next-Generation Sequencing Market is the strongest single volume driver. Sequencing panels require capture probes, custom indexing primers, blocking oligos and library amplification primers. Clinical oncology and prenatal screening programs are increasing the number of sequencing samples without lowering the number of unique oligo designs per panel. Because panels are revised frequently, hospitals and diagnostics labs reorder custom oligos on a recurring schedule, creating predictable revenue for synthesis providers.

The PCR Market remains the legacy engine of oligonucleotide synthesis. Quantitative PCR and digital PCR are used heavily in infectious disease testing, viral load monitoring, GMO detection and gene expression analysis. Each assay uses two primers and one fluorescent hydrolysis probe in most formats, meaning PCR demand creates a high-volume, low-velocity order pattern that keeps synthesis lines fully utilized.

The CRISPR Market is now a meaningful source of guide RNA and repair template production. Gene editing teams need chemically modified single-guide RNAs to improve editing efficiency and reduce immune activation. CRISPR screening libraries require pooled oligo synthesis at a scale that can cover hundreds of thousands of guide sequences per experiment. This workflow pushes synthesis vendors toward higher throughput, better error correction and faster pooling services. At the same time, the Synthetic Biology Market increases demand for longer and more complex DNA assemblies, complementing the volume-led oligo business with higher average selling prices.

The first restraint is biosecurity screening. Customers who order synthetic DNA are now screened against regulated pathogen sequences and potential dual-use sequences. This screening is necessary, but it adds delays and compliance overhead, especially for academic customers with smaller purchasing teams. The International Gene Synthesis Consortium requires member compliance, and regulatory guidance is tightening across major Europe and North America markets.

The second restraint is pricing pressure. Competitive oligo prices continue to fall as automation improves, and large buyers consolidate orders with fewer vendors to obtain volume discounts. This lowers gross margin per base, forcing providers to offset price reductions through better purification yields, lower waste and robust after-sale bioinformatics support. Differentiation through turnaround time can hold pricing, but rapid delivery is difficult to sustain during peak demand cycles.

The third restraint is the shortage of professionals who understand both chemistry and biology. Oligo production requires engineers who can operate synthesizers, purify columns, liquid handlers and QC equipment. A fragmented talent pool can slow capacity expansion and raise onboarding costs, especially for new entrants building manufacturing facilities in North America and Europe.

• Thermo Fisher Scientific, Inc: Offers a broad vertically integrated portfolio spanning primers, probes, gene synthesis and molecular biology reagents, with pricing power anchored in validated qPCR and sequencing workflows.
• Twist Bioscience: Uses high-throughput silicon-based synthesis to supply NGS panels, oligo pools, genes and antibody libraries, combining digital design tools with scalable manufacturing.
• BIONEER CORPORATION: Provides oligonucleotide synthesis, genomics services and molecular diagnostics reagents, with significant manufacturing and product development activity out of South Korea.
• Eton Bioscience, Inc: Targets academic and biotech researchers with custom oligo synthesis, gene synthesis and sequencing services, emphasizing rapid turnaround for smaller institutional orders.
• LGC Biosearch Technologies: Focuses on specialty nucleic acid chemistry, including probes, markers and custom qPCR oligos for diagnostics, food safety and clinical research.
• IBA Lifesciences GmbH: Supplies life science reagents and contract oligo manufacturing for customers that need modified nucleotides, purification and reproducible quality control.
• Eurofins Scientific: Operates as a global life science services company, using its genomics division to supply oligo and gene synthesis for diagnostics, pharma and agbio research.
• Integrated DNA Technologies, Inc.: A leading vendor for custom DNA oligos and CRISPR guide RNA products, recognized for high manufacturing quality and strong customer-facing web ordering tools.
• Quintara Biosciences: Provides Sanger sequencing, gene synthesis and oligo services with a flexible, order-by-order approach built around research lab support.
• GenScript: Specializes in gene synthesis, peptide synthesis and protein engineering, with one of the largest custom gene manufacturing footprints in the industry.

Selected public milestones from 2023-2025 show the direction of operational and product strategy across leading DNA synthesis vendors.

• April 2023: Twist Bioscience expanded its silicon-based oligo pool production capacity in the United States to support high-complexity CRISPR and sequencing customers.
• October 2023: LGC Biosearch Technologies introduced a new line of hydrolysis probes that shortened design-to-production lead times for multiplex qPCR assays.
• February 2024: Integrated DNA Technologies launched an upgraded portfolio of CRISPR guide RNAs with optimized chemical modifications and in silico scoring integration.
• June 2024: GenScript scaled a rapid custom gene synthesis workflow for genes up to 1,500 base pairs, reducing delivery from weeks to days for a subset of high-priority projects.
• November 2024: Eurofins Genomics expanded its German oligo production site to meet stricter diagnostics-grade quality requirements for clinical laboratory customers.
• January 2025: BIONEER CORPORATION expanded dedicated DNA synthesis R&D space in Daejeon, South Korea, signaling greater focus on nucleic acid chemistry and raw material independence.

These actions reflect a common shift from selling unmodified primers to selling validated, application-specific DNA products. Capacity investments are directed at modified oligo synthesis, quality analytics and faster fulfillment rather than simple increases in raw primer volume.

North America is the largest regional market, accounting for 38% of global revenue in 2025. The region benefits from high biopharma R&D spending, rapid adoption of CRISPR tools and the presence of major vendors including Thermo Fisher Scientific, Integrated DNA Technologies, Twist Bioscience and GenScript US operations. Regulatory interactions with the FDA for personalized therapies and companion diagnostics create strong demand for analytically qualified oligos. North America remains the most mature region, with steady but moderating growth of roughly 17% annually.

Europe contributes approximately 26% of global revenue. Germany, the United Kingdom, France and the Nordics lead in academic gene synthesis orders, assay development and diagnostics research. European buyers place strong emphasis on biosecurity compliance, ISO quality systems and environmental reporting. Market growth is slightly below the global average because public research budgets are stable rather than accelerating, although the Benelux region is becoming an attractive hub for cell and gene therapy manufacturing.

Asia-Pacific holds about 28% of global revenue and is the fastest-growing region, with a projected CAGR approaching 21%. China is expanding domestic oligo manufacturing to reduce reliance on imported reagents, while Singapore has built national synthetic biology infrastructure and government-backed biotech parks. South Korea and Japan are strong in NGS-based diagnostics and therapeutic oligonucleotide research, and India is emerging as a low-cost supplier for standard oligo batches. Local regulatory systems remain fragmented, but the broader trend toward centralized GMP manufacturing is creating new capacity faster than most Western markets.

South America, the Middle East and Africa together account for the remaining 8% of revenue. Brazil leads Latin America, supported by agricultural biotechnology and academic genomics programs. The GCC countries are investing in genomic medicine and biobanking, which increases demand for sequencing oligos. These regions start from a lower base but offer strong upside for vendors willing to establish local logistics and technical support. From a strategic standpoint, North America provides margin stability, Europe provides compliance discipline and Asia-Pacific provides the most visible volume growth corridor.

Investment activity in the DNA synthesis market has concentrated around three objectives: scaling enzymatic synthesis platforms, expanding GMP oligo production and acquiring bioinformatics tools that integrate design with manufacturing. Twist Bioscience and GenScript have used capital and strategic contracts to expand gene synthesis and oligo pool capacity. Integrated DNA Technologies, as part of Danaher, has benefited from the parent company's broader life sciences platform and automation capabilities.

Venture funding has flowed into next-generation synthesis companies such as DNA Script and Ansa Biotechnologies, which are developing enzymatic DNA synthesis as a lower-waste alternative to phosphoramidite chemistry. These companies attract funding because they promise simpler reagent handling, lower solvent consumption and easier distribution into decentralized biology laboratories. There is also notable capital deployment in long-read synthesis, where companies aim to address the difficult gap between 200 nt oligos and 2 kb gene fragments.

M&A strategy continues to favor bolt-on acquisition of clinical-grade quality controls, modified nucleotide chemistry and regional service centers. The Antisense Oligonucleotide Market is one of the most active downstream investment targets, as pharmaceutical sponsors seek contract manufacturing partners with validated phosphorothioate chemistry. Buyers are not just purchasing manufacturing capacity; they are purchasing regulatory experience, sequence-to-data integration and the ability to move from research-grade oligos to GMP-grade drug substances without changing suppliers.

The DNA Synthesis Reagents Market is the most important cost anchor in this value chain. Phosphoramidites, acetonitrile, CPG columns, modified nucleotides, enzymes and purification consumables together account for a substantial portion of variable production cost. Price volatility in acetonitrile and logistics costs affects every oligo order, but the strongest long-term price trend is automation-led deflation. Standard unmodified primers now carry very low per-base prices, forcing vendors to differentiate with speed, quality documentation and custom modifications.

Cost structure varies by product type. Standard oligo production in high-throughput formats benefits from economies of scale, with purification and quality control often costing more than the synthesis reaction itself. Custom modified oligos carry higher material costs because modified phosphoramidites are more expensive and often require special coupling chemistry. Gene synthesis is more labor intensive because it involves assembly, cloning and sequence verification, giving efficient providers an advantage through liquid-handling automation and cloud-based construct design.

Gross margins for oligo suppliers typically range from 50% to 65%, with gene synthesis margins on longer constructs generally healthier than short-oligo margins. These margins are under pressure from three directions: increasing competition from regional Asian suppliers, customer consolidation into enterprise purchasing agreements, and higher compliance costs for biosecurity screening. Pricing power has moved toward vendors that supply validated CRISPR reagents, GMP antisense intermediates and NGS-custom capture panels, because buyers are willing to pay a premium for reproducibility and regulatory traceability.

In the forecast period, price per base will continue to decline for standard oligos, but average order value will rise as researchers order longer constructs and modified products. Vendors that can lower solvent consumption, reduce purification rework and shift to data-driven quality control will protect margin. The shift toward enzymatic DNA synthesis may also change cost curve fundamentals by reducing dependence on large solvent volumes, but phosphoramidite chemistry will remain the dominant production method for the next several years due to its installed base and process maturity.

• 1. Service Type
  • 1.1. Oligonucleotide Synthesis
    • 1.1.1. By Type
      • 1.1.1.1. Standard Oligonucleotide Synthesis
      • 1.1.1.2. Custom Oligonucleotide Synthesis
    • 1.1.2. By Length
      • 1.1.2.1. Less than 50 nt
      • 1.1.2.2. 51-100 nt
      • 1.1.2.3. 101-150 nt
      • 1.1.2.4. More than 150 nt
  • 1.2. Gene Synthesis
    • 1.2.1. By Type
      • 1.2.1.1. Custom Gene Synthesis
      • 1.2.1.2. Gene Library Synthesis
    • 1.2.2. By Length
      • 1.2.2.1. Less than 500 nt
      • 1.2.2.2. 501-1000 nt
      • 1.2.2.3. 1001-1500 nt
      • 1.2.2.4. 1501-2000 nt
      • 1.2.2.5. 2001-2500 nt
      • 1.2.2.6. More than 2500 nt
• 2. Application
  • 2.1. Research and Development
    • 2.1.1. Oligonucleotide Synthesis
      • 2.1.1.1. PCR
      • 2.1.1.2. NGS
      • 2.1.1.3. CRISPR
      • 2.1.1.4. Cloning and Mutagenesis
      • 2.1.1.5. Others
    • 2.1.2. Gene Synthesis
      • 2.1.2.1. Synthetic Biology
      • 2.1.2.2. Vaccine Development
      • 2.1.2.3. Genetic Engineering
      • 2.1.2.4. Others
  • 2.2. Diagnostics
  • 2.3. Therapeutics
    • 2.3.1. RNAi Therapies
    • 2.3.2. Antisense Oligonucleotide-based Therapies
    • 2.3.3. Others
• 3. End use
  • 3.1. Biopharmaceutical & Diagnostics Companies
  • 3.2. Academic & Research Institutes
  • 3.3. Contract Research Organizations

• 1. North America
  • 1.1. United States
  • 1.2. Canada
  • 1.3. Mexico
• 2. South America
  • 2.1. Brazil
  • 2.2. Argentina
  • 2.3. Rest of South America
• 3. Europe
  • 3.1. United Kingdom
  • 3.2. Germany
  • 3.3. France
  • 3.4. Italy
  • 3.5. Spain
  • 3.6. Russia
  • 3.7. Benelux
  • 3.8. Nordics
  • 3.9. Rest of Europe
• 4. Middle East & Africa
  • 4.1. Turkey
  • 4.2. Israel
  • 4.3. GCC
  • 4.4. North Africa
  • 4.5. South Africa
  • 4.6. Rest of Middle East & Africa
• 5. Asia Pacific
  • 5.1. China
  • 5.2. India
  • 5.3. Japan
  • 5.4. South Korea
  • 5.5. ASEAN
  • 5.6. Oceania
  • 5.7. Rest of Asia Pacific